Indian Biotech Companies and their Job Openings #pharmaceutical #industry #marketing

Posted On Apr 18 2017 by

#biotech jobs # 05-30-2013, 05:22 AM (This post was last modified: 04-13-2015, 12:03 AM by Administrator .) Biotechnology in India has remained in infant stage for over a decade. Though the institutional research in Biotechnology never ceased to happen, the job prospects in this industry have only followed a downward trend. Much of it might be attributed to the flooding numbers of Biotechnology graduates/postgraduates every year, with no increase in demand at the level of limited number of “good” Biotechnology Companies. Under such a scenario, any lack of enthusiasm and determination to move against the odds can prove fatal for …


UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #industry #pharmacy

Posted On Apr 18 2017 by

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …


Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #fulcrum #pharma

Posted On Apr 18 2017 by

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …


Theravance Biopharma: About Us #pharma #job

Posted On Apr 18 2017 by

#biopharma # Winning Together Theravance Biopharma is a place for advanced thinkers, people who thrive on applying insight and innovation to energize scientific discovery. Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that make a difference in the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S. Europe and certain other countries …


In a bad-news first for pharma reps, more than half of doctors now restrict access #ista #pharma

Posted On Apr 18 2017 by

#pharmaceutical rep # In a bad-news first for pharma reps, more than half of doctors now restrict access It’s no secret that pharma salespeople are barred at the doors of many doctors’ offices. Those doors have been closing one by one for several years. But now, more than half of physician practices restrict reps’ access–and in some specialties, only one in 5 doctors are rep-friendly. Just three years ago, only 35% of U.S. physician practices put tight restrictions on pharma sales staff, according to the latest AccessMonitor report from pharma sales consultants at ZS Associates. As of this spring, it’s …


Pharmaceutical Packaging – Packaging Solutions for Drugs #pharmaceutical #news

Posted On Apr 18 2017 by

#pharma packaging solutions # A Drug is Only as Good as its Packaging Permits How secure are your packaging materials? In recent years, the pharmaceutical industry has been developing drugs that are increasingly sensitive. In order to protect these active ingredients. pharmaceutical packaging requirements were consistently increasing, too. Thanks to our comprehensive material and process expertise we develop packaging solutions for you that are individually tailored to the drug. We can thus offer your products optimal protection. The added value accruing from RAUMEDIC RAUMEDIC develops polymeric packaging solutions and expands them through individual functions that are tailored to your drug. …


Editorial: State s case against Perdue Pharma deserves full hearing #top #generic #drug #companies

Posted On Apr 18 2017 by

#perdue pharma # Editorial: State’s case against Perdue Pharma deserves full hearing While the prescription pain pill epidemic that plagued this region for nearly a decade has been replaced by a heroin epidemic, a lawsuit the state filed against Perdue Pharma, the marker of OxyContin, is still pending. Ironically, an unfavorable ruling against the company regarding a deadline it missed could cost Perdue Pharma more than $1 billion. In a suit dating to when now Speaker of the House Greg Stumbo, D-Prestonsburg, was attorney general, Kentucky claims Purdue Pharma misrepresented OxyContin, resulting in a wave of addiction and increased medical …


Buprenorphine Pipeline #world #pharma

Posted On Apr 18 2017 by

#perdue pharma # The National Alliance of Advocates for Buprenorphine Treatment Buprenorphine (Suboxone . Subutex 3. Zubsolv 4. Bunavail 5. Probuphine 6 ) is an opioid medication used to treat opioid addiction in the privacy of a physician’s office. 1 Buprenorphine can be dispensed for take-home use, by prescription. 1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids. 2 Buprenorphine Pipeline Timeline of buprenorphine products past, present, and future September, 2013 Orexo receives FDA approval for Zubsolv (buprenorphine/naloxone sublingual tablets) launched in September 2013 November, 2014 UPDATE: …


Horizon Pharma Bids $3 Billion For Depomed #pharma #advertising

Posted On Apr 18 2017 by

#horizon pharma # Ireland’s Horizon Pharma launches hostile, $3 billion bid for U.S. rival Ireland s Horizon Pharma is bringing its $3 billion takeover offer for U.S. rival Depomed directly to the company s shareholders after being rebuffed in its attempts to negotiate with Depomed s management. Horizon s HZNP hostile bid for Depomed DEPO . announced on Tuesday. values the Newark, Calif.-based specialty pharmaceutical company at $29.25 per share, which represents a 42% premium over Depomed s Monday closing price. Depomed s share price jumped nearly 40% on the news of Horizon s offer. The Irish manufacturer of drugs …


Tris Pharma announces launch of generic TUSSIONEX #martindale #pharma

Posted On Apr 18 2017 by

#tris pharma # Tris Pharma announces launch of generic TUSSIONEX Published on October 1, 2015 at 8:39 AM Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX , an extended-release suspension containing hydrocodone polistirex and chlorpheniramine polistirex. Tussionex , originally approved in the early 1980 s, had no generic competition until 2010 when Tris Pharma s generic product entered the market under an exclusive distribution agreement with Par Pharmaceuticals. Under the terms of the distribution agreement, Par had the exclusive right to market Tris Pharma s hydrocodone polistirex and chlorpheniramine …